Claudin 1 expression in basal-like breast cancer is related to patient age

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Blanchard, Anne A ^a   Ma, Xiuli ^a   Dueck, Kevin J ^a   Penner, Carla ^a   Cooper, Steven C ^a   Mulhall, Drew ^a   Murphy, Leigh C ^a,b   Leygue, Etienne ^a,b   Myal, Yvonne ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Age; Basal like breast cancer; Claudin 1; Tight junction protein; Tissue microarray

Indexed keywords

CLAUDIN 1; CLAUDIN 4; ESTROGEN RECEPTOR; OSTEOPONTIN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SNAIL; CLDN1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; CANCER GRADING; CANCER GROWTH; CELL FRACTIONATION; CELL MEMBRANE; CELL MIGRATION; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TISSUE MICROARRAY; TUMOR VOLUME; WESTERN BLOTTING; AGE; AGED; BIOSYNTHESIS; BREAST TUMOR; GENE SILENCING; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

AGE FACTORS; AGED; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CLAUDIN-1; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878236278     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-268     Document Type: Article

References (60)

1. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. 3440846, 22522925.
2. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997. 10.1158/0008-5472.CAN-07-2017, 18281472.
3. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
5. Nicholson RI, Johnston SR. Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 2005, 93(Suppl 1):S3-S10.
6. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009, 41:40-47.
7. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7:659-672.
8. Lelievre SA. Tissue polarity-dependent control of mammary epithelial homeostasis and cancer development: an epigenetic perspective. J Mammary Gland Biol Neoplasia 2010, 15:49-63. 10.1007/s10911-010-9168-y, 2861422, 20101444.
9. Anderson JM, Balda MS, Fanning AS. The structure and regulation of tight junctions. Curr Opin Cell Biol 1993, 5:772-778. 10.1016/0955-0674(93)90024-K, 8240820.
10. Mitic LL, Anderson JM. Molecular architecture of tight junctions. Annu Rev Physiol 1998, 60:121-142. 10.1146/annurev.physiol.60.1.121, 9558457.
11. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005, 65:9603-9606. 10.1158/0008-5472.CAN-05-2782, 16266975.
12. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001, 2:285-293. 10.1038/35067088, 11283726.
13. Gonzales-Mariscal L, Garay E, Quiros M. Regulation of Claudins by Posttranslational Modifications and Cell-Signaling Cascades. Current Topics in Membranes 2010, 65:113-150. Elsevier Inc.
14. Gonzalez-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 2008, 1778:729-756. 10.1016/j.bbamem.2007.08.018, 17950242.
15. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002, 156:1099-1111. 10.1083/jcb.200110122, 2173463, 11889141.
16. Leotlela PD, Wade MS, Duray PH, Rhode MJ, Brown HF, Rosenthal DT, et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 2007, 26:3846-3856. 10.1038/sj.onc.1210155, 17160014.
17. Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 2006, 66:5251-5257. 10.1158/0008-5472.CAN-05-4478, 16707450.
18. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005, 115:1765-1776. 10.1172/JCI24543, 1150288, 15965503.
19. Blanchard AA, Skliris GP, Watson PH, Penner C, Tomes L, Murphy LC, et al. Claudin 1, 3 and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 2009, 454:647-656. 10.1007/s00428-009-0770-6, 19387682.
20. Kramer F, White K, Kubbies M, Swisshelm K, Weber BH. Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum Genet 2000, 107:249-256. 10.1007/s004390000375, 11071387.
21. Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev 2005, 57:919-928. 10.1016/j.addr.2005.01.006, 15820559.
22. Tokes AM, Kulka J, Paku S, Szik A, Paska C, Novak PK, et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005, 7:R296-R305. 10.1186/bcr983, 1064136, 15743508.
23. Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 2007, 20:139-143.
24. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
25. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4:e6146. 10.1371/journal.pone.0006146, 2702084, 19582160.
26. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
27. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006, 95:616-626. 10.1038/sj.bjc.6603295, 2360679, 16880783.
28. Skliris GP, Hube F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, et al. Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology 2008, 52:355-369. 10.1111/j.1365-2559.2007.02955.x, 2253716, 18269587.
29. Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC, et al. Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res 2003, 63:1954-1961.
30. Alarmo EL, Parssinen J, Ketolainen JM, Savinainen K, Karhu R, Kallioniemi A. BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett 2009, 275:35-43. 10.1016/j.canlet.2008.09.028, 18980801.
31. Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem 2007, 102:829-839. 10.1002/jcb.21509, 17914743.
32. Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, et al. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol 2013, 26:485-495. 10.1038/modpathol.2012.187, 23222490.
33. cBio Portal for Cancer Genomics. 2013, , http://www.cbioportal.org/public-portal/
34. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607. 10.1038/nature11003, 3320027, 22460905.
35. French AD, Fiori JL, Camilli TC, Leotlela PD, O'Connell MP, Frank BP, et al. PKC and PKA phosphorylation affect the subcellular localization of claudin-1 in melanoma cells. Int J Med Sci 2009, 6:93-101. 2658888, 19305641.
36. Bock CT, Toan NL, Koeberlein B, Song H, Chin R, Zentgraf H, et al. Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology 2008, 51:432-443. 10.1159/000209672, 19321929.
37. Gao F, Huang C, Lin M, Wang Z, Shen J, Zhang H, et al. Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res Clin Oncol 2009, 135:739-747. 10.1007/s00432-008-0508-x, 19015875.
38. Huang L, Muthuswamy SK. Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. Curr Opin Genet Dev 2010, 20:41-50. 10.1016/j.gde.2009.12.001, 3015045, 20093003.
39. Jakab C, Rusvai M, Galfi P, Szabo Z, Szabara A, Kulka J. Expression of claudin-1, -3, -4, -5 and -7 proteins in low grade colorectal carcinoma of canines. Histol Histopathol 2010, 25:55-62.
40. Strongin AY. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 2006, 25:87-98. 10.1007/s10555-006-7892-y, 16680575.
41. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996, 383:441-443. 10.1038/383441a0, 8837777.
42. Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 2004, 229:1090-1096.
43. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:1087-1097. 10.1158/1055-9965.EPI-06-1008, 17548669.
44. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010, 10:71-81. 10.2174/156652410791065381, 20205680.
45. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001, 6:419-429. 10.1023/A:1014734930781, 12013531.
46. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer 2011, 10:15. 10.1186/1476-4598-10-15, 3045364, 21314937.
47. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318. 10.1080/00313020701329914, 17558857.
48. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000, 2:84-89. 10.1038/35000034, 10655587.
49. Lopez D, Niu G, Huber P, Carter WB. Tumor-induced upregulation of Twist, Snail, and Slug represses the activity of the human VE-cadherin promoter. Arch Biochem Biophys 2009, 482:77-82. 10.1016/j.abb.2008.11.016, 19046938.
50. Martinez-Estrada OM, Culleres A, Soriano FX, Peinado H, Bolos V, Martinez FO, et al. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J 2006, 394:449-457. 10.1042/BJ20050591, 1408675, 16232121.
51. Park SH, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol 2008, 22:2085-2098. 10.1210/me.2007-0512, 18550773.
52. Ikenouchi J, Matsuda M, Furuse M, Tsukita S. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci 2003, 116:1959-1967. 10.1242/jcs.00389, 12668723.
53. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y. Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res 2001, 12:469-476.
54. Ravindranath A, Yuen HF, Chan KK, Grills C, Fennell DA, Lappin TR, et al. Wnt-beta-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer 2011, 105:542-551. 10.1038/bjc.2011.269, 3170969, 21772333.
55. Li Y, Yang W, Yang Q, Zhou S. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype. Histol Histopathol 2012, 27:475-484.
56. Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs 2011, 193:23-40. 10.1159/000320174, 21051859.
57. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005, 16:251-263. 10.1016/j.cytogfr.2005.01.009, 15871923.
58. Alarmo EL, Kuukasjarvi T, Karhu R, Kallioniemi A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 2007, 103:239-246. 10.1007/s10549-006-9362-1, 17004110.
59. Naber HP, Wiercinska E, Pardali E, van Laar T, Nirmala E, Sundqvist A, et al. BMP-7 inhibits TGF-beta-induced invasion of breast cancer cells through inhibition of integrin beta(3) expression. Cell Oncol (Dordr ) 2012, 35:19-28.
60. Rodriguez-Martinez A, Alarmo EL, Saarinen L, Ketolainen J, Nousiainen K, Hautaniemi S, et al. Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes. BMC Med Genomics 2011, 4:80. 10.1186/1755-8794-4-80, 3229454, 22118688.